209 related articles for article (PubMed ID: 33558338)
1. "3G" Trial: An RNA Editing Signature to Guide Gastric Cancer Chemotherapy.
An O; Song Y; Ke X; So JB; Sundar R; Yang H; Rha SY; Lee MH; Tay ST; Ong X; Tan ALK; Ng MCH; Tantoso E; Chen L; Tan P; Yong WP;
Cancer Res; 2021 May; 81(10):2788-2798. PubMed ID: 33558338
[TBL] [Abstract][Full Text] [Related]
2. Clinically applicable 53-Gene prognostic assay predicts chemotherapy benefit in gastric cancer: A multicenter study.
Zhu L; Wang H; Jiang C; Li W; Zhai S; Cai X; Wang X; Liao L; Tao F; Jin D; Chen G; Xia Y; Mao JH; Li B; Wang P; Hang B
EBioMedicine; 2020 Nov; 61():103023. PubMed ID: 33069062
[TBL] [Abstract][Full Text] [Related]
3. An individualized prognostic signature for gastric cancer patients treated with 5-Fluorouracil-based chemotherapy and distinct multi-omics characteristics of prognostic groups.
Li X; Cai H; Zheng W; Tong M; Li H; Ao L; Li J; Hong G; Li M; Guan Q; Yang S; Yang D; Lin X; Guo Z
Oncotarget; 2016 Feb; 7(8):8743-55. PubMed ID: 26840027
[TBL] [Abstract][Full Text] [Related]
4. A seven-Gene Signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the MAGIC trial.
Smyth EC; Nyamundanda G; Cunningham D; Fontana E; Ragulan C; Tan IB; Lin SJ; Wotherspoon A; Nankivell M; Fassan M; Lampis A; Hahne JC; Davies AR; Lagergren J; Gossage JA; Maisey N; Green M; Zylstra JL; Allum WH; Langley RE; Tan P; Valeri N; Sadanandam A
Ann Oncol; 2018 Dec; 29(12):2356-2362. PubMed ID: 30481267
[TBL] [Abstract][Full Text] [Related]
5. Somatic mutation of DNAH genes implicated higher chemotherapy response rate in gastric adenocarcinoma patients.
Zhu C; Yang Q; Xu J; Zhao W; Zhang Z; Xu D; Zhang Y; Zhao E; Zhao G
J Transl Med; 2019 Apr; 17(1):109. PubMed ID: 30944005
[TBL] [Abstract][Full Text] [Related]
6. Identification of a molecular signature of prognostic subtypes in diffuse-type gastric cancer.
Kim SK; Kim HJ; Park JL; Heo H; Kim SY; Lee SI; Song KS; Kim WH; Kim YS
Gastric Cancer; 2020 May; 23(3):473-482. PubMed ID: 31773340
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of a prognostic and predictive 32-gene signature for gastric cancer.
Cheong JH; Wang SC; Park S; Porembka MR; Christie AL; Kim H; Kim HS; Zhu H; Hyung WJ; Noh SH; Hu B; Hong C; Karalis JD; Kim IH; Lee SH; Hwang TH
Nat Commun; 2022 Feb; 13(1):774. PubMed ID: 35140202
[TBL] [Abstract][Full Text] [Related]
8. A gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patients.
Kim HK; Choi IJ; Kim CG; Kim HS; Oshima A; Michalowski A; Green JE
PLoS One; 2011 Feb; 6(2):e16694. PubMed ID: 21364753
[TBL] [Abstract][Full Text] [Related]
9. Discovery and validation of an expression signature for recurrence prediction in high-risk diffuse-type gastric cancer.
Lee IS; Sahu D; Hur H; Yook JH; Kim BS; Goel A
Gastric Cancer; 2021 May; 24(3):655-665. PubMed ID: 33523340
[TBL] [Abstract][Full Text] [Related]
10. Analysis of microRNA expression profiles reveals a 5‑microRNA prognostic signature for predicting overall survival time in patients with gastric adenocarcinoma.
Zhao R; Zhao L; Xu X; Xu H
Oncol Rep; 2019 May; 41(5):2775-2789. PubMed ID: 30864737
[TBL] [Abstract][Full Text] [Related]
11. DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.
Ott K; Rachakonda PS; Panzram B; Keller G; Lordick F; Becker K; Langer R; Buechler M; Hemminki K; Kumar R
Ann Surg Oncol; 2011 Sep; 18(9):2688-98. PubMed ID: 21347786
[TBL] [Abstract][Full Text] [Related]
12. Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis.
Cheong JH; Yang HK; Kim H; Kim WH; Kim YW; Kook MC; Park YK; Kim HH; Lee HS; Lee KH; Gu MJ; Kim HY; Lee J; Choi SH; Hong S; Kim JW; Choi YY; Hyung WJ; Jang E; Kim H; Huh YM; Noh SH
Lancet Oncol; 2018 May; 19(5):629-638. PubMed ID: 29567071
[TBL] [Abstract][Full Text] [Related]
13. Tumour expression of leptin is associated with chemotherapy resistance and therapy-independent prognosis in gastro-oesophageal adenocarcinomas.
Bain GH; Collie-Duguid E; Murray GI; Gilbert FJ; Denison A; McKiddie F; Ahearn T; Fleming I; Leeds J; Phull P; Park K; Nanthakumaran S; Matula KM; Grabsch HI; Tan P; Welch A; Schweiger L; Dahle-Smith A; Urquhart G; Finegan M; Petty RD
Br J Cancer; 2014 Mar; 110(6):1525-34. PubMed ID: 24569475
[TBL] [Abstract][Full Text] [Related]
14. A 16-mRNA signature optimizes recurrence-free survival prediction of Stages II and III gastric cancer.
Peng K; Chen E; Li W; Cheng X; Yu Y; Cui Y; Li Q; Wang Y; Xu X; Tang C; Gan L; Yu S; Liu T
J Cell Physiol; 2020 Jul; 235(7-8):5777-5786. PubMed ID: 32048287
[TBL] [Abstract][Full Text] [Related]
15. Genome-wide analysis to identify a novel distant metastasis-related gene signature predicting survival in patients with gastric cancer.
Hu BL; Xie MZ; Li KZ; Li JL; Gui YC; Xu JW
Biomed Pharmacother; 2019 Sep; 117():109159. PubMed ID: 31247467
[TBL] [Abstract][Full Text] [Related]
16. Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300.
Bang YJ; Ruiz EY; Van Cutsem E; Lee KW; Wyrwicz L; Schenker M; Alsina M; Ryu MH; Chung HC; Evesque L; Al-Batran SE; Park SH; Lichinitser M; Boku N; Moehler MH; Hong J; Xiong H; Hallwachs R; Conti I; Taieb J
Ann Oncol; 2018 Oct; 29(10):2052-2060. PubMed ID: 30052729
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study.
Bang YJ; Kang YK; Catenacci DV; Muro K; Fuchs CS; Geva R; Hara H; Golan T; Garrido M; Jalal SI; Borg C; Doi T; Yoon HH; Savage MJ; Wang J; Dalal RP; Shah S; Wainberg ZA; Chung HC
Gastric Cancer; 2019 Jul; 22(4):828-837. PubMed ID: 30911859
[TBL] [Abstract][Full Text] [Related]
18. Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept "3G" Trial.
Yong WP; Rha SY; Tan IB; Choo SP; Syn NL; Koh V; Tan SH; Asuncion BR; Sundar R; So JB; Shabbir A; Tan CS; Kim HS; Jung M; Chung HC; Ng MCH; Tai DW; Lee MH; Wu J; Yeoh KG; Tan P;
Clin Cancer Res; 2018 Nov; 24(21):5272-5281. PubMed ID: 30045931
[No Abstract] [Full Text] [Related]
19. Genome-wide identification of a novel miRNA-based signature to predict recurrence in patients with gastric cancer.
Yang Y; Qu A; Zhao R; Hua M; Zhang X; Dong Z; Zheng G; Pan H; Wang H; Yang X; Zhang Y
Mol Oncol; 2018 Dec; 12(12):2072-2084. PubMed ID: 30242969
[TBL] [Abstract][Full Text] [Related]
20. A DNA methylation signature to improve survival prediction of gastric cancer.
Peng Y; Wu Q; Wang L; Wang H; Yin F
Clin Epigenetics; 2020 Jan; 12(1):15. PubMed ID: 31959204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
